Additionally, these compounds specifically target the FOXO3a pathway to inhibit breast cancer, and the inhibiting effectiveness of these compounds even significantly diminished when FOXO3a was eliminated (Manoharan et al., 2023). This evidence concerns the gene FOXO3 and breast carcinoma.